Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
July 13 2023 - 1:00AM
Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”),
a leading biotech company that transforms cells into solutions that
promote wellbeing and sustainability, today announced the
appointment of Lorne Abony to the Company’s Board of Directors,
effective as of July 11, 2023.
Abony is a successful entrepreneur who has decades of experience
building and scaling multi-billion-dollar global businesses – both
public and private companies – across multiple industries. He is a
globally recognized leader who has invested, directly or
indirectly, in more than 20 cellular agriculture and cultivated
food companies. Bringing his expertise to Pluri's board, he will
contribute to the Company's strategic growth plans by utilizing its
cell-expansion technology platform across various sectors, such as
cultivated food and cellular agriculture.
Mr. Lorne Abony
"Lorne's visionary leadership has made a profound impact across
companies, industries, and continents. He understands how to
develop and scale both public and private businesses – and how to
inspire people along the way. Lorne has driven innovation and
progress in cultivated food, as a well-respected leader in the
space,” said Pluri CEO and President, Yaky Yanay.
“We are excited about the potential that Lorne brings to Pluri’s
Board, and believe that he will make a tremendous contribution to
our bold and ambitious growth strategy,” added Pluri Chairman of
the Board, Zami Aberman.
“Cultivated foods and cellular agriculture are the future. These
rapidly growing industries present a tremendous market opportunity
for pioneering companies like Pluri,” Mr. Abony said. “I’m thrilled
to join Pluri’s Board. This proven pioneer in biotech has
extraordinary potential to add tremendous value across a range of
industries, and create a cleaner, healthier, and more sustainable
planet, utilizing its cell expansion technology.”
As a founder and executive, Mr. Abony has scaled major ventures
including FUN Technology Ltd, Emmac Life Sciences Limited and
NuuVera Inc. He has raised over $1.7 billion through public and
private debt and equity markets. In 2011, Mr. Abony received
Canada’s Ernst & Young Entrepreneur of the Year Award for his
founding and leadership of Mood Media Corporation (Mood). Mr. Abony
scaled Mood from a pre-revenue startup to the world’s largest
in-store media company with more than 3,300 employees, offices in
47 countries and over $750 million in annual revenue, before
selling the company to a private equity firm. He was also featured
on the hit network T.V. series, “Undercover Boss.” Mr. Abony is
currently chair and board member of several companies in the field
of cultivated food, AI, and technology such as VitroLabs Inc.,
AmyInsights, and Einride A.B.
About Pluri Inc.
Pluri is pushing the boundaries of science and engineering to
create cell-based products for commercial use and is pioneering a
biotech revolution that promotes global wellbeing and
sustainability. The Company’s technology platform, a patented and
validated state-of-the-art 3D cell expansion system, advances novel
cell-based solutions for a range of initiatives— from medicine and
climate change to food scarcity, animal cruelty and beyond. Pluri’s
method is uniquely accurate, scalable, cost-effective, and
consistent from batch to batch. Pluri currently operates in the
field of regenerative medicine, food-tech and biologics and aims to
establish partnerships that leverage the Company’s 3D cell-based
technology to additional industries that require effective, mass
cell production. To learn more, visit us
at www.pluri-biotech.com or follow us
on LinkedIn and Twitter.
Safe Harbor Statement
This press release contains express or implied forward-looking
statements within the Private Securities Litigation Reform Act of
1995 and other U.S. Federal securities laws. For example, Pluri is
using forward-looking statements when it discusses that its cell
expansion technology has extraordinary potential across a range of
industries. These forward-looking statements and their implications
are based on the current expectations of the management of Pluri
only and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those
described in the forward-looking statements. The following factors,
among others, could cause actual results to differ materially from
those described in the forward-looking statements about Pluri:
changes in technology and market requirements; Pluri may encounter
delays or obstacles in launching and/or successfully completing its
clinical trials, if necessary; its products may not be approved by
regulatory agencies, its technology may not be validated as it
progresses further and its methods may not be accepted by the
scientific community; it may be unable to retain or attract key
employees whose knowledge is essential to the development of its
products; unforeseen scientific difficulties may develop with its
processes; its products may wind up being more expensive than it
anticipates; results in the laboratory may not translate to equally
good results in real clinical settings; its patents may not be
sufficient; its products may harm recipients or consumers; changes
in legislation with an adverse impact; inability to timely develop
and introduce new technologies, products and applications; loss of
market share and pressure on pricing resulting from competition,
which could cause the actual results or performance of Pluri to
differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluri undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Pluri reference is made to Pluri's reports
filed from time to time with the Securities and Exchange
Commission.
Media ContactsInvestors: Director of Investor
Relations, Aviva Banczewski,
investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il U.S.
Media: Nathan Miller at nathan@miller-ink.com / Meira Feinman at
meira@miller-ink.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/0b707a5d-77fc-4f7f-91d4-e2bb4475d911
Pluri (NASDAQ:PLUR)
Historical Stock Chart
From Apr 2024 to May 2024
Pluri (NASDAQ:PLUR)
Historical Stock Chart
From May 2023 to May 2024